Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

2(28.6%)

Phase 3

2(28.6%)

7Total

Phase 1(3)

Phase 2(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05174416Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM

Role: lead

NCT06206278Phase 2Terminated

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Role: lead

NCT05135871Phase 1Completed

Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects

Role: lead

NCT05621525Phase 1Terminated

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Role: lead

NCT06032936Phase 1Terminated

BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations

Role: lead

NCT05629390Phase 3Completed

Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

Role: lead

NCT05019794Phase 2Unknown

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Role: lead

All 7 trials loaded